<DOC>
	<DOCNO>NCT01511900</DOCNO>
	<brief_summary>The primary objective study evaluate safety escalate multiple dos 2 week CAT 1004 compare placebo patient Type 2 diabetes ( T2D ) . Secondary objective include evaluation pharmacokinetics ( PK ) pharmacodynamics escalate multiple dos CAT-1004 patient T2D .</brief_summary>
	<brief_title>A Multiple Ascending Dose Study CAT-1004 Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>A patient must meet follow criterion study : Age 18 65 year inclusive Screening . Diagnosis T2D : For Part I : Treated diet exercise , without metformin ( stable ≥ 2 month ) . HbA1c ≥ 7.0 % ≤ 10.0 % diet exercise alone , ≥6.5 % ≤ 9.0 % metformin . For Part II : • Stable metformin ≥ 2 month HbA1c ≥ 7.0 % ≤ 10.0 % . Satisfies one following : Females childbearing potential : nonpregnant nonlactating ; surgically sterile postmenopausal 2 year least 1 year follicle stimulate hormone assessment ( FSH ) great equal 40 IU/L ; OR Males : surgically sterile , abstinent , patient partner utilize acceptable contraceptive method 3 month last study dose . On stable diet body mass index ( BMI ) : 25 40 kg/m2 inclusive Screening weight stable ( ± 4 kg ) &gt; 6 week prior Screening . A patient eligible follow criterion apply : Use prescription medication allow medication within 30 day plan admission clinic . Allowed medication include metformin , antihypertensive , lipidlowering medication , thyroid replacement therapy , lowdose aspirin ( 81 mg/day ) , proton pump inhibitor antidepressant . Prescribed dose medication must stable 2 month time first dose . Clinically significant abnormality physical examination vital sign screen Clinically significant electrocardiogram ( ECG ) abnormality assess investigator . Clinically significant laboratory result assess Investigator . The patient history clinically significant medical disease include significant allergy ( except untreated , asymptomatic seasonal allergy time dose ) , hematological , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurological disease , T2D , hypertension , dyslipidemia , hypothyroidism depression . History presence malignancy within past 5 year . History Type 1 diabetes clinically significant cardiovascular disease ( include history unstable angina , acute myocardial infarction , coronary artery bypass graft , percutaneous coronary intervention , New York Heart Association Class III IV congestive heart failure within 6 month prior screen ) clinically significant renal disease . History alcohol substance abuse eat disorder within 2 year , OR regular use alcohol within 6 month ( &gt; 14 unit alcohol per week ; 1 unit = 150 mL wine , 360 mL beer , 45 mL 40 % alcohol ) . Use investigational drug participation investigational study within 30 day prior screen 5 halflives study agent , whichever longer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>